How Seer (SEER) Is Rewriting Its Story With New Targets And Activist Pressure

Seer’s analyst price target has shifted from US$3.29 to US$4.00, changing the implied upside that some investors will be ...

Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer

Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer’s Proteograph® ...
Nasdaq

Seer, Inc. and Korea University Launch First Large-Scale Study to Identify Early-Onset Cancer Biomarkers Using Proteograph ONE Assay

Seer and Korea University launch a study to identify blood-based cancer biomarkers using advanced mass spectrometry and AI analytics. Seer, Inc. and Korea University have launched a groundbreaking ...
Nasdaq

Seer, Inc. to Showcase Innovations in Proteomics at US HUPO 2025 Annual Conference

Seer, Inc. will present innovative findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia from February 22-26, 2025, where they will highlight advancements in ...
Seeking Alpha

Seer, Inc. (SEER) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley. Before we begin, I'd like to remind our listeners that ...
GEN

Seer Showcases Deep Proteomics Capabilities, Announces Co-Marketing Deal with Thermo Fisher Scientific

At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic insights that complement and strengthen other forms of omics data. Through various sessions at the meeting, the ...
Seeking Alpha

The Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas Roelofs

Raises Concerns About the Board’s Continued Deference to Chair and CEO Dr. Omid Farokhzad in Light of His Track Record of Value Destruction Highlights Recently Filed Stockholder Lawsuit Against Seer ...